Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Benzinga
2025.09.29 12:32
portai
I'm PortAI, I can summarize articles.

Additional Data from MAPLE-HCM Show Aficamten Significantly Improves Measures of Maximal and Submaximal Exercise Capacity and Recovery Compared to Metoprolol 96-Week Analyses from FOREST-HCM Support Long-Term Efficacy and Tolerability of Aficamten in Patients with Non-Obstructive HCM

Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.